Brokerages Set AngioDynamics, Inc. (NASDAQ:ANGO) PT at $18.67

AngioDynamics, Inc. (NASDAQ:ANGO) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $18.6667.

A number of analysts recently commented on ANGO shares. Canaccord Genuity Group dropped their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. Finally, Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th.

AngioDynamics Stock Down 0.2%

NASDAQ ANGO opened at $12.77 on Tuesday. AngioDynamics has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The stock has a market cap of $527.66 million, a price-to-earnings ratio of -17.03 and a beta of 0.34. The business has a fifty day moving average of $12.03 and a 200-day moving average of $11.32.

Institutional Trading of AngioDynamics

Hedge funds have recently bought and sold shares of the company. Kotler Kevin purchased a new stake in AngioDynamics in the 4th quarter worth approximately $21,997,000. Weber Capital Management LLC ADV acquired a new position in AngioDynamics in the 4th quarter valued at $17,978,000. UBS Group AG lifted its stake in shares of AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after purchasing an additional 501,881 shares during the period. Millennium Management LLC lifted its stake in shares of AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after purchasing an additional 393,682 shares during the period. Finally, Nuveen LLC boosted its holdings in shares of AngioDynamics by 40.5% during the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock worth $16,629,000 after purchasing an additional 373,110 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.